US Patent issued for new multi-functional thermal ablation device developed by CPSI Biotech

OWEGO, NY — CPSI Biotech is proud to announce the issuance of a patent (US Pat#: 9,566,105) by the United States Patent and Trademark Office covering device design and method of use of a new multi-functional thermal ablation technology to be used for the treatment of diseases ranging from cancer or heart disease.

This multi-functional thermal ablation technology offers the ability to apply both heat and cryogenic energy to tissue using a single device, enabling controlled, real-time application of a dual thermal ablation strategy. The dual thermal ablation system enables the delivery of a multitude of therapeutic treatment options, including heat and cold, along with anti-cancer agents, alone or in any combination as desired. Dr. John M. Baust, President and CEO of CPSI Biotech, stated “This technological platform will offer a physician the ability to apply both heat and cryotherapy in conjunction or alone, all from a single probe to ablate targeted tissue. The ability to deliver multiple ablative energy insults in a single device will eliminate the need for multiple systems and probe switching during a procedure, thereby reducing patient risk, procedure time and overall cost.”

Regarding CPSI Biotech’s future plans for the technology, Baust stated, “We continue to work on the development of this innovative technology. Our goal is to move through the R&D phase and into pilot studies with a clinical collaborator with this technology over the next year.”

Click Here to read the full Press Release: US Patent issued for new multi-functional thermal ablation device

View other CPSI Biotech news and recent patent announcements

Presentations at CRYO2016 Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Studies focused on the FrostBite device platform and cancer response to cryoablation highlight the potential use of this next generation technology for the treatment of pancreatic and esophageal cancer.

August 3, 2016 – Owego, NY – The need for the development of new devices and strategies to treat cancer was front and center at this year’s annual meeting of the Society for Cryobiology held in Ottawa, Canada in the session “Cool Developments in Cryomedicine”. This 2 part, 4-hour session featured 9 presentations focused on new developments in the use of cryo for disease treatment. As part of the session, CPSI scientists presented three studies focusing on molecular studies and device development in the areas of prostate (John M. Baust, Ph.D., CPSI President), pancreatic (Anthony Robilotto, MS., CPSI Engineer) and esophageal cancer (Kristi Snyder, Ph.D., Principal Scientist). Central to these studies was the incorporation of several of CPSI’s new device technologies including the PSN cryoablation device, FrostBite cryoablation catheter and EsoAblate cryoprobe. The FrostBite and EsoAblate cryoprobes are under development for the minimally invasive endoscopic based treatment of pancreatic and esophageal cancer, among other gastrointestinal cancers. The studies included discussion of cancer cell response to freezing, device design and characterization analysis as well as data from a series of studies conducted using tissue engineered pancreas and esophageal cancer models. The presentations also included results from preliminary in vivo studies conducted in conjunction with collaborators at Johns Hopkins Medical which demonstrated the successful translation of CPSI’s engineering and life science development into functional systems capable of delivering of an ultra-cold, highly lethal insult (ablative dose) within a matter of minutes.

Click here to read the full press release: Presentations Feature CPSI’s FrostBite GI Cancer Cryoablation Platform

Contact us to learn more about CPSI’s Cryoablation Medical Device Research & Development Programs

View other CPSI Biotech news and recent patent announcements

post

SmartThaw Presentation Given at Cryo2016

CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

OWEGO, NY — CPSI Biotech scientists just returned from presenting at the Society for Cryobiology Annual Meeting (Cryo2016) in Ottawa, CA (July 24-27). CPSI’s involvement included a scientific poster presentation and demonstration of CPSI’s new SmartThaw™ device designed to improve the thawing process of frozen cell and tissue products.

This scientific study on SmartThaw™ conducted by a team of researchers from CPSI and led by Dr. Kristi Snyder (Director of Operations and Principal Scientist) and Kimberly Santucci (Research Scientist). “SmartThaw™ System is a new device for controlled and rapid dry thawing of cryopreserved (frozen) samples and products. This study demonstrated that sample thawing with SmartThaw™ improves processing of frozen products while also providing equivalent, and in several cases, improved sample viability post-thaw” stated Ms. Santucci. Speaking to the technology, Dr. Snyder stated “We introduced the prototype system this spring and have been collecting end-user feedback and input for final design and performance focus. These insights have aided in the final design engineering which is now in process. As a result of these ongoing activities, we are targeting commercial launch in late Q3 2016.”

The poster titled “Assessment of SmartThaw™: A novel dry thawing system for cryopreserved cell products” focused on the improved processing and outcome that can be obtained using SmartThaw™. The poster highlighted studies conducted on CHO, PC-3, human endothelial, and mesenchymal stem cells.

Click here to read the full press release: CPSI researchers present a scientific poster on the SmartThaw™ cell thawing system.

View the Poster Presented at the Society for Cryobiology conference: Cryo 2016 Smart Thaw Poster

View other CPSI Biotech news and recent patent announcements